Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2030

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2030

  • July 2020 •
  • 100 pages •
  • Report ID: 5921860 •
  • Format: PDF
‘Acute Respiratory Distress Syndrome (ARDS)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Acute Respiratory Distress Syndrome (ARDS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Acute Respiratory Distress Syndrome (ARDS) Understanding
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.
The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions. The few symptoms of ARDS are shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risks factors that may escalate the risk for ARDS; this involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

<>Acute Respiratory Distress Syndrome (ARDS) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of ARDS, Severity-specific Incidence of ARDS and Incidence of ARDS by Risk Factors scenario of Acute Respiratory Distress Syndrome (ARDS) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

<>Acute Respiratory Distress Syndrome (ARDS) Detailed Epidemiology Segmentation
• In the 7MM, the total incident population of ARDS is estimated to be 7,99,872 in 2017.
• Generally, the highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which sepsis was the primary risk factor for ARDS.
• The estimates show a higher incidence of ARDS in the United States with 4, 95,655 cases in 2017.

Scope of the Report
• The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Acute Respiratory Distress Syndrome (ARDS).
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Acute Respiratory Distress Syndrome (ARDS), Total Diagnosed and Treated Cases of Acute Respiratory Distress Syndrome (ARDS).

Report Highlights
• Eleven-Year Forecast of Acute Respiratory Distress Syndrome (ARDS)
• 7MM Coverage
• Total Incident Population of ARDS
• Severity-specific Incidence of ARDS
• Incidence of ARDS by Risk Factors
• Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is estimated to increase at a CAGR of 1.07%
• Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is projected to rise at a CAGR of 0.92%.

Key Questions Answered
• What is the disease risk, burden and unmet needs of Acute Respiratory Distress Syndrome (ARDS)?
• What is the historical Acute Respiratory Distress Syndrome (ARDS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Respiratory Distress Syndrome (ARDS)?
• Out of the countries mentioned above, which country would have the highest prevalent population of Acute Respiratory Distress Syndrome (ARDS) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Acute Respiratory Distress Syndrome (ARDS) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.
• Quantify patient populations in the 7MM Acute Respiratory Distress Syndrome (ARDS) market to improve product design, pricing, and launch plans.
• The Acute Respiratory Distress Syndrome (ARDS) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Acute Respiratory Distress Syndrome (ARDS) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

<>• Patient Segmentation
• Disease Risk and Burden

<>• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030